Point of view: The concept of an inhalable nanoparticle-based siRNA therapy for betacoronavirus infections

In 2019, a global pandemic evolved with currently more than 7 million deaths caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Previous betacoronaviruses, such as SARS-CoV and MERS-CoV, have crossed the species barrier, causing limited but severe epidemics, which illustrates the risk of future pandemics arising from emerging betacoronaviruses. Therefore prospectively, it seems to be of great relevance to develop a broad-spectrum therapy against betacoronaviruses.

We present a concept of an inhalable siRNA formulation that is effective against the broadest possible spectrum of betacoronaviruses. The intended drug carrier is formed by PBAEs containing spermine and oleylamine side chains, ensuring effective encapsulation and reducing toxicity, which can additionally be coupled to an ACE-2 receptor antibody or similar targeting strategies for active targeting. It also represents a significant step forward in the field of antiviral therapies. As we continue to refine and test our formulation, we aim to provide a robust, scalable solution that can be deployed rapidly in response to future outbreaks. Ultimately, the success of our inhalable siRNA formulation could transform the way we approach pandemic preparedness, providing a powerful means of both treating and preventing viral infections.